A randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor prognosis germ cell tumors (MRC TE23, CRUK 05/014, ISRCTN53643604).

被引：1
|
作者：
Huddart, R. A.
Gabe, R.
Cafferty, F.
Pollock, P.
White, J. D.
Shamash, J.
Stenning, S. P.
机构：
[1] Inst Canc Res, Sutton, Surrey, England
[2] Med Res Council Clin Trials Unit, London, England
[3] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[4] St Bartholomews Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4508
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4508
引用
收藏
页数：1
相关论文
共 22 条
  • [21] Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).
    Feldman, Darren R.
    Hu, James S.
    Patil, Sujata
    Reuter, Victor E.
    Srinivas, Sandy
    Stadler, Walter Michael
    Costello, Brian Addis
    Milowsky, Matthew I.
    Appleman, Leonard Joseph
    Dorff, Tanya B.
    Bromberg, Maria
    Joseph, Gabriella
    Funt, Samuel Aaron
    Bajorin, Dean F.
    Bosl, George J.
    Quinn, David I.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: A randomized medical research council European organization for research and treatment of cancer study
    Kaye, SB
    Mead, GM
    Fossa, S
    Cullen, M
    deWit, R
    Bodrogi, I
    van Groeningen, C
    Sylvester, R
    Collette, L
    Stenning, S
    De Prijck, L
    Lallemand, E
    deMulder, P
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) : 692 - 701
123